Gross Profit 21,961 11,998 66,440 63,973
Operating Expenses 12,389 8,730 46,520 49,984
Research and Development 785 1,138 4,108 4,696
Income from Operations 8,787 2,130 15,812 9,293
Total Other Income 130 203 653 414
Net Income Before Tax 8,917 2,333 16,465 9,707
Income Tax Expense 3,201 624 6,037 3,168
Net Income $5,716 $1,709 $10,428 $6,539
Net Income per Diluted Share $0.59 $0.17 $1.04 $0.66
Average Shares Outstanding (mil) 9.7 10.0 10.0 10.0
Selected Balance Sheet Information
($000s) March 31, 2008 Dec. 31, 2007 March 31, 2007
Cash and Marketable
Securities $27,933 $13,166 $16,944
Accounts Receivable
- Trade $12,052 $23,280 $8,257
Inventory $11,530 $17,421 $15,459
Total Assets $78,149 $80,836 $71,151
Current Liabilities $10,574 $16,619 $9,556
Working Capital $44,612 $41,659 $38,705
Total Debt $0 $0 $0
Shareholders' Equity $65,552 $63,002 $60,435
About Matrixx Initiatives, Inc.
Matrixx Initiatives, Inc. is engaged in the development, manufacture
and marketing of over-the-counter healthcare products that utilize
innovative drug delivery systems. Zicam, LLC, its wholly-owned subsidiary,
produces, markets and sells Zicam(R) and Nasal Co
'/>"/>
| SOURCE Matrixx Initiatives, Inc. Copyright©2008 PR Newswire. All rights reserved |